vs
Side-by-side financial comparison of Nano Dimension Ltd. (NNDM) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $57.8M, roughly 1.6× Nano Dimension Ltd.). Vericel Corp runs the higher net margin — 25.0% vs -171.1%, a 196.1% gap on every dollar of revenue. Vericel Corp produced more free cash flow last quarter ($12.8M vs $-21.1M).
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
NNDM vs VCEL — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.8M | $92.9M |
| Net Profit | $-98.8M | $23.2M |
| Gross Margin | 43.1% | 78.7% |
| Operating Margin | -155.1% | 24.1% |
| Net Margin | -171.1% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $-0.45 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $92.9M | ||
| Q3 25 | — | $67.5M | ||
| Q2 25 | — | $63.2M | ||
| Q1 25 | — | $52.6M | ||
| Q4 24 | $57.8M | $75.4M | ||
| Q3 24 | — | $57.9M | ||
| Q2 24 | $28.4M | $52.7M | ||
| Q1 24 | — | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $-553.0K | ||
| Q1 25 | — | $-11.2M | ||
| Q4 24 | $-98.8M | $19.8M | ||
| Q3 24 | — | $-901.0K | ||
| Q2 24 | $-79.2M | $-4.7M | ||
| Q1 24 | — | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | 43.1% | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | 45.8% | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | — | 24.1% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | -155.1% | 24.5% | ||
| Q3 24 | — | -4.3% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | — | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | — | 7.5% | ||
| Q2 25 | — | -0.9% | ||
| Q1 25 | — | -21.4% | ||
| Q4 24 | -171.1% | 26.3% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | -279.4% | -8.9% | ||
| Q1 24 | — | -7.5% |
| Q4 25 | — | $0.46 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | $-0.45 | $0.40 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | $-0.35 | $-0.10 | ||
| Q1 24 | — | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $317.2M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $860.0M | $354.6M |
| Total Assets | $902.5M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | $317.2M | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | $231.8M | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | — | $354.6M | ||
| Q3 25 | — | $321.9M | ||
| Q2 25 | — | $306.8M | ||
| Q1 25 | — | $295.5M | ||
| Q4 24 | $860.0M | $292.0M | ||
| Q3 24 | — | $257.5M | ||
| Q2 24 | $870.3M | $243.0M | ||
| Q1 24 | — | $233.9M |
| Q4 25 | — | $488.0M | ||
| Q3 25 | — | $453.3M | ||
| Q2 25 | — | $435.6M | ||
| Q1 25 | — | $424.6M | ||
| Q4 24 | $902.5M | $432.7M | ||
| Q3 24 | — | $390.4M | ||
| Q2 24 | $911.0M | $376.8M | ||
| Q1 24 | — | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.9M | $15.0M |
| Free Cash FlowOCF − Capex | $-21.1M | $12.8M |
| FCF MarginFCF / Revenue | -36.5% | 13.8% |
| Capex IntensityCapex / Revenue | 3.8% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $22.1M | ||
| Q2 25 | — | $8.2M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | $-18.9M | $22.2M | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | $-30.7M | $18.5M | ||
| Q1 24 | — | $7.2M |
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | $-21.1M | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $-6.8M |
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | -36.5% | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% | ||
| Q1 24 | — | -13.3% |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | 3.8% | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NNDM
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
